Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI
NCT ID: NCT04063800
Last Updated: 2019-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
195 participants
OBSERVATIONAL
2018-06-26
2018-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Radiomic features are quantitative features extracted from medical imaging, supposed to be correlated with tumor heterogeneity.
We aim to build and test three predictive models (clinical, radiomic and combined models).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer
NCT04983459
Functional Medical Imaging Quantization in Prostate Cancer
NCT03376360
Prediction of Lymph Node Invasion for Prostate Adenocarcinoma
NCT04909957
Model of Predicting Biochemical Recurrence After Radical Prostate Cancer Based on Pre-treatment PSMA PET / MR Image Features
NCT06604377
Prostate Biopsies With Target Lesion on MRI
NCT04692207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients underwent radical prostatectomy
* High-risk prostate cancers: at least 1 criteria (pt3a/pT3b/pT4, R1, Gleason score \> 7)
Exclusion Criteria
* No analyzable pre-operative MRI
* proof of lymph-node involvement (cN1/2 or pN1/2)
* post-operative PSA \> 0.04ng/mL
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest
Brest, Brittany Region, France
Centre Hospitalier de Cornouaille
Quimper, Brittany Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PREBOP (29BRC18.0108)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.